Phase 2 study of sodium phenylbutyrate in ALS
Explore this paper's citation graph
Summary
While the majority of subjects tolerated higher dosages of NaPB, the lowest dose, 9 g/day, was therapeutically efficient in improving histone acetylation levels, and NaPB was safe and tolerable.
- Type
- article
- Published
- 2009-01-01
- Cited by
- 157
- References
- 30
- OpenAlex
- https://openalex.org/W2128206335
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12390136
Keywords
Histone deacetylase inhibitor, Medicine, Pharmacology, Tolerability, Dose
References
- Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate.
- Sodium Phenylacetate Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis in SJL/J Mice at Multiple Steps1
- A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
- El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
- Alternative pathway therapy for urea cycle disorders: twenty years later.
- Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway.
- Differential expression of inflammation‐ and apoptosis‐related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis
- Neurotoxin‐Related Research: From the Laboratory to the Clinic
- Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate
- Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice
- Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays
- A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
- Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis
- Trial of celecoxib in amyotrophic lateral sclerosis
- Treatment of spinal muscular atrophy by sodium butyrate
- A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
- Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice
- The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
- Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter.
- Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
Cited by
- The potential of epigenetic therapies in neurodegenerative diseases
- Developing and validating a high-throughput drug screen in a zebrafish model of amyotrophic lateral sclerosis
- A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies
- Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.
- Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis
- Multiple roles of HDAC inhibition in neurodegenerative conditions
- The promise and perils of HDAC inhibitors in neurodegeneration
- Pathogenic Considerations in Sporadic Inclusion-Body Myositis, a Degenerative Muscle Disease Associated With Aging and Abnormalities of Myoproteostasis
- Trials with ‘epigenetic’ drugs: An update
- New therapeutic targets for amyotrophic lateral sclerosis
- Emerging drugs for amyotrophic lateral sclerosis
- Potential utility of biomarkers in the diagnosis and treatment of amyotrophic lateral sclerosis
- Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention.
- Sodium phenylbutyrate reverses lysosomal dysfunction and decreases amyloid-β42 in an in vitro-model of inclusion-body myositis.
- Histone deacetylases and their role in motor neuron degeneration
- Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era
- Screening for Active Small Molecules in Mitochondrial Complex I Deficient Patient's Fibroblasts, Reveals AICAR as the Most Beneficial Compound
- Clinical and Experimental Applications of Sodium Phenylbutyrate
- Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease.
- Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition.
Related papers
- Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
- Inhibition of Class IIb Histone Deacetylase Significantly Improves Cloning Efficiency in Mice1
- Recent progress in the development of assays suited for histone deacetylase inhibitor screening.
- Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor.
- Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase.
- Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
- Supplemental Table 3 from The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
- Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL